Asston Pharmaceuticals Limited is an Indian pharmaceutical and nutraceutical manufacturer and exporter operating under the brand name “Asston”. The company primarily caters to domestic and African markets, focusing on affordable, high-quality formulations.

Core Operations:

• Product Categories: Tablets, Capsules, Syrups, Oral Powders (Sachets, Dry Syrups), External Preparations (Ointments, Creams, Gels, Lotions), Injectables (LVP & SVP).
• Business Model:
  • Direct manufacturing and marketing.
  • Contract manufacturing and loan licensing for corporate clients.
• Production Facility: Located in Ambernath, Maharashtra, with separate floors for:
  • Pharmaceuticals (FDA-governed)
  • Nutraceuticals (FSSAI-governed)

Manufacturing Capabilities:

• Tablets: Capacity of 8–9 crore tablets/month; average production 5–6 crore/month.
• Syrups (Nutraceuticals): ~37.5 kiloliters/month.
• Sachets: 30–40 lakh/month (depending on weight).
• Facility includes QA/QC labs, warehouse, and is FDA-certified (Central and State) and NQA-accredited.

Quality and Regulatory Compliance:

• WHO-GMP certified contract manufacturers.
• Own regulatory department and tie-ups with NABL-accredited labs.
• Complies with Quality Management System (QMS) standards.
• Operations fall under green and orange environmental zones.
• Over 150 registered trademarks for formulations.

Products and Markets:

• Broad range includes generic medicines, pediatric drugs, eye drops, NTTB (New to the Basket) treatments.
• Distributed across more than 10 countries, including South Africa and West Africa.
• Focus on price-sensitive markets with low-cost, quality formulations.

Growth and Development:

• Founded: April 16, 2019, as a private limited company.
• Acquired Ferron Lifecare’s nutraceutical plant in Ambernath in April 2024.
• Converted to a public limited company on August 29, 2024.
• FDA approval for pharmaceutical manufacturing received on December 2, 2024.
• Leadership Team: Dr. Ashish Sakalkar, Mrs. Saili More, and Mr. Sachin Badakh.
• Team Size: 50+ employees and expanding.

Strategic Initiatives:

• 5-year contracts with WHO-GMP-certified manufacturers for various formulations.
• Ongoing expansion with a new loan license deal in Gujarat for ointment production.
• In-house regulatory team supports dossier preparation and global compliance for exports.